A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection

Table 4 Antibiogram result of PE

Antibiotics	Antibiogram result								Total	SEN	P value
	Non-ESBL-E				ESBL-E
	S	I	R	SEN	S	I	R	SEN
Ciprofloxacin	304	24	265	51.3	39	5	220	14.8	857	40.0	< 0.001
Levofloxacin	246	66	246	44.1	35	18	219	12.9	874	32.2	< 0.001
P/T	580	14	8	96.3	167	35	69	61.6	873	85.6	< 0.001
Ceftazidime	540	43	16	90.2	26	49	196	9.6	870	65.1	< 0.001
C/S	590	7	3	98.3	166	31	75	61.0	872	86.7	< 0.001
Cefepime	533	23	45	88.7	18	46	207	6.6	872	63.2	< 0.001
Aztreonam	561	1	30	94.8	18	2	242	6.9	854	67.8	< 0.001
Amikacin	595	4	3	98.8	233	4	35	85.7	874	94.7	< 0.001
Tobramycin	438	115	39	74.0	127	53	81	48.7	853	66.2	< 0.001
Carbapenem	602	0	0	100.0	228	0	44	83.8	874	95.0	< 0.001
TMP-SMX	312	1	288	51.9	82	0	188	30.4	871	45.2	< 0.001
Polymyxin	600	0	2	99.7	267	0	5	98.2	874	99.2	0.033
Doxycycline	271	123	204	45.3	73	43	155	26.9	869	39.6	< 0.001
Minocycline	371	80	139	62.9	96	39	126	36.8	851	54.9	< 0.001
Tigecycline	590	0	2	99.7	238	0	7	97.1	837	98.9	0.004
Cefixime	45	0	134	25.1	1	0	235	0.4	415	11.1	< 0.001
Latamoxef	53	0	2	96.4	50	0	8	86.2	113	91.2	0.095
Cefdinir	1	0	20	4.8	1	0	93	1.1	115	1.7	0.333
Ceftriaxone	388	0	3	99.2	2	0	45	4.3	438	89.0	< 0.001
Cefmetazole	92	0	0	100.0	4	0	14	22.2	110	87.3	< 0.001
Ceftizoxime	39	0	0	100.0	0	0	10	0.0	49	79.6	< 0.001

S, Sensitive; I, Intermediate; R, Resistant; SEN, Sensitivity, %; P/T, piperacillin/tazobactam; C/S, cefoperazone/sulbactam; TMP-SMX, trimethoprim–sulfamethoxazole